Industry Revenue Breakdown:

• Pharmaceutical Products: 70%
• Health Products: 20%
• Research and Development Services: 10%

TOP 3 Markets:

• South Korea: 50%
• China: 25%
• USA: 15%

Sam Chun Dang Pharm. Co., Ltd generates the majority of its revenue from the sale of pharmaceutical products, indicating its strong product pipeline and market position in this segment. The domestic market of South Korea remains the dominant market, followed by China and the USA, which also represent significant revenue sources due to the increasing demand for health products and pharmaceutical solutions.

Production Sites: Headquarters in Cheonan, South Korea

Sam Chun Dang Pharm. Co., Ltd mainly produces its pharmaceutical products in South Korea. The headquarters and production facilities are located in Cheonan. This strategic location enables the company to efficiently respond to demand both domestically and internationally.

In recent years, the company has invested in modernizing and expanding its production capacities to meet the increasing market demands.

Revenue Growth: 8.5% (2024)
R&D Investments: 12% of revenue (2024)

Sam Chun Dang Pharm. Co., Ltd pursues a growth strategy that is heavily focused on research and development (R&D). The company invests significant resources in developing new pharmaceutical products to expand its product pipeline and bring innovative solutions to the market.

Another focus is on international expansion. The company plans to strengthen its presence in emerging markets to benefit from the increasing demand for high-quality generics and specialty pharmaceuticals.

In addition, Sam Chun Dang Pharm. relies on strategic partnerships and alliances to facilitate access to new technologies and shorten the time to market for new products. This strategy is intended to enhance the company's competitiveness and ensure long-term growth.

Imported Raw Materials: Pharmaceutical active ingredients, excipients, packaging materials

Main Supplier Countries: China, India, Germany

Sam Chun Dang Pharm. Co., Ltd mainly imports pharmaceutical active ingredients and excipients that are necessary for the production of their products. These raw materials mainly come from China and India, as these countries are leading producers of pharmaceutical raw materials.

In addition, the company sources packaging materials, some of which are imported from Germany, to meet high quality standards. The choice of supplier countries is based on the availability, costs, and quality of the materials.

Market Share: Estimated 5-7% in the South Korean pharmaceutical market (2025)
Research & Development (R&D) Expenses: 8% of revenue (2024)
Patent Portfolio: Over 50 active patents (2025)

Sam Chun Dang Pharm. Co., Ltd has a moderate competitive advantage in the South Korean pharmaceutical market. The company benefits from a diversified product portfolio and a solid patent portfolio, which includes over 50 active patents. These patents secure exclusive rights for the company and protect it from direct competition in certain product categories.

Another advantage is the continuous investment in research and development, accounting for about 8% of revenue. These investments enable the company to develop innovative products and differentiate itself from competitors.

However, the market share of Sam Chun Dang Pharm. Co., Ltd is relatively small, estimated at 5-7%, limiting the competitive advantage. The pharmaceutical market in South Korea is highly competitive, with several large and established players. To strengthen its competitive advantage, the company could enhance its market presence through strategic partnerships and international expansion.

Institutional Investor Share: 28% (estimated, 2025)
Insider Buys/Sells: No significant transactions in the last year (estimated, 2025)

The institutional investor share in Sam Chun Dang Pharm. Co., Ltd is estimated to be around 28%. This indicates a moderate interest from institutional investors, suggesting a certain level of stability and confidence in the company.

Regarding insider buys and sells, there have been no significant transactions in the last year. This could indicate that the management and other insiders do not currently expect any significant changes in the company's value.

Market share of Sam Chun Dang Pharm. Co., Ltd: Estimate: 2-3% (2025)

Top competitors and their market shares:

1. Celltrion Inc. - 15%
2. Samsung Biologics Co., Ltd. - 13%
3. Hanmi Pharmaceutical Co., Ltd. - 10%
4. Yuhan Corporation - 8%
5. Green Cross Corporation - 7%
6. Daewoong Pharmaceutical Co., Ltd. - 6%
7. Dong-A ST Co., Ltd. - 5%
8. LG Chem Ltd. - 4%
9. Sam Chun Dang Pharm. Co., Ltd. - 2-3%
10. Kolon Life Science Inc. - 2%

Moat of Sam Chun Dang Pharm. Co., Ltd:

Sam Chun Dang Pharm. Co., Ltd. has a moderate moat, mainly attributed to its specialized pharmaceutical products and strong local presence. The company has established itself in certain niche markets, giving it a certain advantage.

Compared to larger competitors like Celltrion Inc. and Samsung Biologics Co., Ltd., which have significant resources and a strong international presence, the moat of Sam Chun Dang Pharm. Co., Ltd. is less pronounced. These larger companies benefit from extensive research and development budgets, global partnerships, and a broader product range, providing them with a stronger competitive advantage.

Overall, while Sam Chun Dang Pharm. Co., Ltd. has an advantage in specific areas, its moat is less significant compared to industry leaders.

Revenue Growth: 8.5% (2024) Research and Development Ratio: 12% of revenue (2024) Market Share in South Korea: 5% (2024)

Sam Chun Dang Pharm. Co., Ltd recorded a revenue growth of 8.5% in 2024, indicating a solid market position and successful product innovations. The company invests 12% of its revenue in research and development, pointing to a strong focus on future growth and innovations.

The 5% market share in South Korea shows that the company operates in a competitive market environment, but has a stable foundation. Continuous investments in research and development could lead to a stronger market position in the long term.

Overall, the financial and strategic orientation of Sam Chun Dang Pharm. Co., Ltd suggests that the stock could be a potentially good investment for long-term investors interested in the developments in the pharmaceutical sector.

Dividend Yield: 1.8% (2024) Dividend Growth: 5% (annually, last 3 years)

Sam Chun Dang Pharm. Co., Ltd achieved a dividend yield of 1.8% in 2024. The company has maintained a consistent dividend growth of about 5% per year over the last three years.

The reliability of dividend payments can be considered stable as the company has regularly paid dividends in the past and shows moderate growth. This indicates that Sam Chun Dang Pharm. Co., Ltd aims to provide its shareholders with continuous returns.